Kuros Biosciences Past Earnings Performance
Past criteria checks 0/6
Kuros Biosciences's earnings have been declining at an average annual rate of -5.3%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 52% per year.
Key information
-5.3%
Earnings growth rate
27.7%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 52.0% |
| Return on equity | -24.2% |
| Net Margin | -40.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11
Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Revenue & Expenses BreakdownBeta
How Kuros Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | -14 | 32 | 0 |
| 30 Sep 23 | 27 | -15 | 28 | 0 |
| 30 Jun 23 | 20 | -16 | 24 | 0 |
| 31 Mar 23 | 19 | -15 | 22 | 0 |
| 31 Dec 22 | 18 | -15 | 19 | 0 |
| 30 Sep 22 | 17 | -13 | 18 | -1 |
| 30 Jun 22 | 15 | -11 | 16 | -3 |
| 31 Mar 22 | 14 | -9 | 15 | -1 |
| 31 Dec 21 | 14 | -8 | 14 | 0 |
| 30 Sep 21 | 13 | -7 | 13 | 2 |
| 30 Jun 21 | 12 | -6 | 11 | 4 |
| 31 Mar 21 | 8 | -9 | 11 | 4 |
| 31 Dec 20 | 4 | -12 | 10 | 4 |
| 30 Sep 20 | 3 | -12 | 9 | 4 |
| 30 Jun 20 | 3 | -12 | 9 | 3 |
| 31 Mar 20 | 3 | -12 | 8 | 4 |
| 31 Dec 19 | 3 | -11 | 7 | 5 |
| 30 Sep 19 | 2 | -11 | 7 | 6 |
| 30 Jun 19 | 1 | -12 | 8 | 7 |
| 31 Mar 19 | 1 | -12 | 8 | 7 |
| 31 Dec 18 | 1 | -12 | 9 | 7 |
| 30 Sep 18 | 0 | -13 | 11 | 4 |
| 30 Jun 18 | 0 | -15 | 13 | 1 |
| 31 Mar 18 | 0 | -16 | 14 | 0 |
| 31 Dec 17 | 1 | -16 | 15 | 0 |
| 30 Sep 17 | 1 | -15 | 14 | 1 |
| 30 Jun 17 | 1 | -13 | 13 | 2 |
| 31 Mar 17 | 1 | -17 | 15 | 1 |
| 31 Dec 16 | 1 | -20 | 17 | 0 |
| 30 Sep 16 | 1 | -19 | 15 | 0 |
| 30 Jun 16 | 1 | -18 | 14 | 0 |
| 31 Mar 16 | 1 | -12 | 9 | 0 |
| 31 Dec 15 | 0 | -6 | 4 | 0 |
Quality Earnings: KURN is currently unprofitable.
Growing Profit Margin: KURN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KURN is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare KURN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KURN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: KURN has a negative Return on Equity (-24.2%), as it is currently unprofitable.